A statement released earlier today by Vetr Inc. about Biogen Inc (NASDAQ:BIIB) bumps the target price to $346.47
- Updated: September 24, 2016
Stating as potential upside of 0.12%, Vetr Inc. raised the target price of Biogen Inc (NASDAQ:BIIB) to $346.47
On 09/12/2016, Vetr Inc. released a statement for Biogen Inc (NASDAQ:BIIB) bumped up the target price from $0.00 to $346.47 that suggested an upside of 0.13%.
Boasting a price of $309.98, Biogen Inc (NASDAQ:BIIB) traded -0.71% lower on the day. With the last stock price close up 13.37% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Biogen Inc has recorded a 50-day average of $309.56 and a two hundred day average of $275.71. Volume of trade was down over the average, with 881,641 shares of BIIB changing hands under the typical 1,828,500
See Chart Below
Biogen Inc has a 52 week low of $223.02 and a 52 week high of $333.65 with a P/E ratio of 18.26 The company’s market cap is currently $0.
In addition to Vetr Inc. reporting its target price, a total of 19 firms have reported on the stock. The consensus target price is $333.47 with 6 firms rating the stock a strong buy, 8 firms rating the stock a buy, 9 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Biogen Inc (NASDAQ:BIIB)
Biogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc., a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies. It also develops late stage product candidates, including Aducanumab (BIIB037) for the treatment of Neurodegeneration, and Nusinersen for other programs.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.